GlassScriptPhysician profile
Devalkumar Jitendrabhai Rajyaguru
NPI 1083951719
$4,657.47
in general payments reported to CMS, 2019-2025
46 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $129 · 2022: $462 · 2023: $896 · 2024: $1,096 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.63 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $458.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.47 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $390.06 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $388.23 | 2019-2025 | |
| Daiichi Sankyo INC. | $321.88 | 2019-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $243.00 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $215.87 | 2022-2025 | |
| Gilead Sciences, INC. | $202.81 | 2022-2025 | Trodelvy |
| Celgene Corporation | $198.54 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $137.81 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $121.80 | 2019-2025 | Erleada, Rybrevant |
| Seagen INC. | $97.40 | 2019-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $92.03 | 2019-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $86.60 | 2024-2025 | Alunbrig, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $85.35 | 2019-2025 | Libtayo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $85.07 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Incyte Corporation | $81.35 | 2019-2023 | Jakafi |
| Glaxosmithkline, LLC. | $81.02 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $69.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.73 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $59.88 | 2019-2024 | Onivyde |
| Array Biopharma INC | $59.38 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $52.02 | 2019-2024 | Xtandi |
| Tempus Ai, INC | $49.95 | 2024-2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $48.16 | 2022-2024 | Tavalisse, Rezlidhia |
| Genentech USA, INC. | $48.08 | 2019-2025 | Phesgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.70 | 2019-2025 | |
| Stemline Therapeutics INC. | $41.61 | 2023-2024 | Orserdu |
| Kyowa Kirin, INC. | $35.41 | 2023-2024 | Poteligeo |
| Pharmacosmos Therapeutics INC. | $33.70 | 2022-2023 | Monoferric |
| Eisai INC. | $33.04 | 2023-2024 | |
| Puma Biotechnology, INC. | $31.89 | 2019-2024 | |
| Exelixis INC. | $31.48 | 2023-2024 | Cabometyx |
| Tesaro, INC. | $30.84 | 2019 | |
| Clovis Oncology, INC. | $29.97 | 2019 | |
| Genmab U.S., INC. | $29.40 | 2023 | Tivdak |
| Global Blood Therapeutics, INC. | $25.30 | 2022 | |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Coherus Oncology, INC. | $21.03 | 2023 | |
| Grifols USA, LLC | $19.60 | 2019 | |
| Beone Medicines USA, INC. | $17.62 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $15.64 | 2024 | Besremi |
| Beigene USA, INC. | $15.34 | 2023 | Brukinsa |
| Cti Biopharma Corp. | $15.32 | 2022 | |
| Taiho Oncology, INC. | $13.19 | 2022 | |
| Emd Serono, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devalkumar Rajyaguru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.